PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
1184518303	CYP2C19*1; CYP2C19*9	PMID:21692664	CYP2C19	CYP2C19 *9 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and troglitazone as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluoxetine; ketoconazole; sertraline; troglitazone
1448276439	rs2032583	PMID:26704739	ABCB1	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.	no	= 0.442	73		Unknown	Efficacy	false	Efficacy was measured as change in Hamilton Rating Scale for Depression (HAM-D-17). Patients were randomized to a high-dose arm and a normal-dose arm. Assessment made after 0, 7, 14, 21, and 28 days of treatment.	amitriptyline; citalopram; escitalopram; nortriptyline; paroxetine; Selective serotonin reuptake inhibitors; sertraline; trimipramine; venlafaxine
1184483601	rs57098334	PMID:18452396	SLC6A4	Allele (AGCCCACCC)12 is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele (AGCCCACCC)9.	no	> 0.05	64		Unknown	Efficacy	false	Response was measured using HAM-D and CGI- scores. There was no significant difference between the frequency of the 9/10, 10/10, 9/12, 10/12, and 12/12 genotypes and responses to sertraline.	sertraline
1450931954	rs5441	PMID:30324302	GNB3	Genotype GG is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to genotypes AA + AG.	yes	= 0.004	100		Near Eastern	Efficacy	false	Patients with the GG genotype were significantly more likely to respond to sertraline than those with the AA or AG genotypes. Response was defined by achieving at least a 50% reduction in baseline HDRS score during six weeks of sertraline treatment. Variant referred to as A-350G in the paper.	sertraline
1184169374	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*17; CYP2D6*41	PMID:23545896	CYP2D6	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	no	= 0.619	184		Multiple groups, predominantly European ancestry (90.2%)	Toxicity	false	The association is for impact of CYP2D6 (P=0.619) or CYP2C19 (P=0.391) on the occurrence of significant side effects in all trials overall (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders. A similar approach was taken for side effects.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1449718371	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:16580768	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is not associated with concentrations of sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	no		45		Multiple groups	Metabolism/PK	false		sertraline
1183617538	CYP2C19*2	PMID:15168101	CYP2C19	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with increased plasma concentrations when treated with sertraline in people with Depressive Disorder, Major.	not stated		2		European	Metabolism/PK	false	Association with dose-corrected drug plasma concentrations. Study investigated the effects of multiple antidepressants on side effects and response. In the text one PM patient on sertraline was mentioned with higher plasma level and an additional presented in table, therefore no p-value. Only *2 was genotype in study cohort.	sertraline
1450664569	rs17878459	PMID:21692664	CYP2C19	Allele C is not associated with sensitivity to ketoconazole, omeprazole, sertraline, ticlopidine, tranylcypromine or troglitazone as compared to allele G.	no					Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine. The construct includes E92D and I331V."	ketoconazole; omeprazole; sertraline; ticlopidine; tranylcypromine; troglitazone
1184169499	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:23545896	CYP2C19	CYP2C19 *1/*1 + *1/*17 + *2/*17 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	no	= 0.391	184		Multiple groups, predominantly European ancestry (90.2%)	Toxicity	false	The association is for impact of CYP2D6 (P=0.619) or CYP2C19 (P=0.391) on the occurrence of significant side effects in all trials overall (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders. A similar approach was taken for side effects.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
981502225	rs495794	PMID:22795047	SRP19	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.017	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The G allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the G allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the A allele."	citalopram; fluoxetine; paroxetine; sertraline
1184137349	CYP2C19 normal metabolizers	PMCID:PMC2014324	CYP2C19	CYP2C19 normal metabolizers is associated with increased inhibition of sertraline N-demethylation by anti-CYP2C8/9/19 when exposed to sertraline as compared to CYP2C19 poor metabolizers.	not stated		12		Unknown	Metabolism/PK	false	Part of study that was designed to define the kinetic behaviour of sertraline N-demethylation in human liver microsomes.	sertraline
1451407120	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:31792367	SLC6A4	SLC6A4 HTTLPR long form (L allele) is associated with increased likelihood of Sexual Dysfunctions, Psychological due to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.04	67		Unknown	Toxicity	false		sertraline
1184518542	CYP2C19*1; CYP2C19*16	PMID:21692664	CYP2C19	CYP2C19 *16 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and ticlopidine as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluoxetine; ketoconazole; sertraline; ticlopidine
1450664546	rs181297724	PMID:21692664	CYP2C19	Allele C is associated with decreased sensitivity to fluoxetine, ketoconazole, sertraline or ticlopidine as compared to allele G.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine. Construct included A161P and I331V but not *2 key SNP."	fluoxetine; ketoconazole; sertraline; ticlopidine
1183617434	CYP2D6*1; CYP2D6*4	PMCID:PMC2291379	CYP2D6	CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.	yes	= 0.03	833		European	Dosage,Efficacy	false	(*4*4 vs. *1*1; this SNP was the only SNP assayed and this method could not detect *5.) SSRIs were grouped together for this analysis (32.5 % of patients were taking paroxetine; 13.4% fluvoxamine;11.6% fluoxetine; 7.3% sertraline;4.6% citalopram;0.1% escitalopram.  Mean SSRI dose was significantly lower at the 3rd  prescription (difference 0.17 DDD) but not significant for the following prescriptions.   Genotypes were not in Hardy-Weinberg equilibrium; frequency below is for a larger population that included patients treated with other antidepressants.	citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1450931565	rs6311	PMID:30221791	HTR2A	Allele T is not associated with likelihood of Nausea and Vomiting due to sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.16	65		Unknown	Toxicity	false	This variant is referred to in the paper as the -1438 A/G SNP. Please note that alleles have been complemented to the positive strand.	sertraline
981502232	rs153549	PMID:22795047	REEP5	Allele A is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.0089	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The A allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the A allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the G allele."	citalopram; fluoxetine; paroxetine; sertraline
1448531914	rs114577328	PMCID:PMC5367948		Allele C is associated with increased risk of drug-induced liver injury when treated with fenofibrate, sertraline, terbinafine or ticlopidine as compared to allele G.	yes	= 7.0e-8	862	10588	European	Toxicity	false	The GWAS cohort includes DILI cases from a variety of drugs. The association with rs114577328 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI.  rs114577328 was used as proxy marker for HLA-A*33:01 with high LD ( r2=0.98).	fenofibrate; sertraline; terbinafine; ticlopidine
1184518535	CYP2C19*1; CYP2C19*15	PMID:21692664	CYP2C19	CYP2C19 *15 is not associated with sensitivity to celecoxib, fluconazole, ketoconazole, sertraline, ticlopidine and troglitazone as compared to CYP2C19 *1.	no					Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluconazole; ketoconazole; sertraline; ticlopidine; troglitazone
1184137354	CYP2D6 poor metabolizers	PMID:8941024	CYP2D6	CYP2D6 poor metabolizers are not associated with differences in for sertraline and desmethylsertraline pharmacokinetics when treated with sertraline in healthy individuals as compared to CYP2D6 normal metabolizers.	no		20		Unknown	Metabolism/PK	false	Subjects phenotyped with debrisoquin.	sertraline
1450931941	rs45476395	PMID:30324302	GNB3	Allele T is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele A.	no	= 0.920	100		Near Eastern	Efficacy	false	No significant association between this variant and changes in HDRS score during 6 weeks of sertraline treatment. Variant referred to as A657T in the paper.	sertraline
981502239	rs153560	PMID:22795047	REEP5	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.0036	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The G allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the G allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the A allele."	citalopram; fluoxetine; paroxetine; sertraline
1183689490	rs28401781	PMID:24192121	ABCB1	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.267	284		East Asian	Efficacy	false	Allele T was more frequent in the responders group. This association did not remain statistically significant after correction for false-discovery rate and genotypes were not significantly associated. Please note; alleles have been complemented to the plus chromosomal strand. This SNP was in strong LD with rs4148739.	citalopram; fluoxetine; paroxetine; sertraline
1450933348	CYP2C19*1; CYP2C19*17	PMID:31649299	CYP2C19	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	not stated	< 0.012	553		European	Metabolism/PK	false	Among CYP2C19 UMs, the mean estimated serum concentration of both sertraline and N-desmethylsertraline was 10% lower compared to NMs (p = 0.012 and p = 0.016, respectively). No significant difference in metabolic ratio between UMs and NMs was observed (p = 0.517). The OR for having =1 TDM measurements below the target concentration range of 30 nM in CYP2C19 UMs was 1.31 (p = 0.098, CI: 0.95–1.80) compared to NMs.	sertraline
827921657	rs2235040	PMID:22641028	ABCB1	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.	yes	= 4.0E-4	424		Unknown	Toxicity	false	This SNP was significant alone and as part of a haplotype of 6 ABCB1 variants.	citalopram; fluvoxamine; paroxetine; sertraline; venlafaxine
1448102384	rs4343	PMID:27262302	ACE	Genotype GG is not associated with response to sertraline in people with Depressive Disorder.	no	= 0.999	55	71	Near Eastern	Efficacy	false	as compared to fluoxetine. Patients with major depressive disorder were randomized to receive sertraline or fluoxetine. Depression severity determined w/ the 21-item Hamilton Rating Scale for Depression (HAMD-21) before and after the treatment. Response calculated based on 50 % reduction in the reported scores. Given allele frequencies were compared between treatment groups in the responsive patients only.	sertraline
1184509880	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:22885912	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	yes	= 0.004	88		East Asian	Efficacy	false	For statistical power, the samples were enriched with the l/l carriers 5-HTTLPR polymorphism, L/L carriers are rare in Koreans.	fluoxetine; sertraline
1184169142	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*17; CYP2D6*41	PMID:23545896	CYP2D6	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with treatment response when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	no	= 0.743	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	The association is for impact of CYP2D6 (P=0.743) or CYP2C19 (P=0.939) on overall response (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1447950063	CYP2B6*1; CYP2B6*6; CYP2B6*9	PMID:26830411	CYP2B6	CYP2B6 *6/*9 + *1/*6 + *6/*6 is associated with increased concentrations of sertraline in people with Depressive Disorder, Major as compared to CYP2B6 *1/*1.	yes	= 0.0001	50		Unknown	Metabolism/PK	false	2B6*1/*6 n=13 2B6*6/*6 n=7 2B6*6/*9 n=3 *1/*1=27	sertraline
655386291	rs6295	PMID:19800133	HTR1A	Genotype CC is associated with increased likelihood of non-response when treated with paroxetine and sertraline in people with Panic Disorder as compared to genotypes CG + GG.	yes	= 0.001	102		European	Efficacy	false		paroxetine; sertraline
1183921586	CYP2D6*1; CYP2D6*1xN; CYP2D6*2	PMID:22775532	CYP2D6	CYP2D6 *1/*1xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype phenotype) is not associated with differences in treatment response when treated with citalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to CYP2D6 normal metabolizer.	no	> 0.05	39		Unknown	Efficacy	false	CYP2D6 metabolizer status had no significant effect on clinical response (p>0.05).32 patients were CYP2D6 EMs, 2 were UMs, 4 were IMs, and 1 patient was a PM. Exploratory association analysis of response to all 108 drug trials found a significant effect of CYP2D6 metabolizer status on response (Fisher's exact test: p=0.021) when comparing the patients with reduced CYP2D6 activity (IMs and PMs) to EMs or UMs, but no information regarding the direction of the association is given. AmpliChip CYP450 test, which detects up to 33 alleles, including 7 duplications in the CYP2D6 and 3 alleles in the CYP2C19 gene. PM, IM, EM, or UM status for CYP2D6 and PM or EM status for CYP2C19 using phenotyping software available with the AmpliChip CYP450 test.	citalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1183960116	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:19800133	SLC6A4	SLC6A4 HTTLPR long form (L allele) is not associated with differences in response when treated with paroxetine or sertraline in people with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele).	no		102		European	Efficacy	false	5-HT transporter insert/deletion promoter region polymorphism, PCR (forward primer 5-TGAATGCCAGCACCTAACCC-3; reverse primer 5-TTCTGGTGCCACCTAGACGC-3) was used to generate 406-base pair ( short) and 450-base pair (long) fragments	paroxetine; sertraline
1184518588	CYP2C19*1; CYP2C19*19	PMID:21692664	CYP2C19	CYP2C19 *19 is associated with decreased sensitivity to fluoxetine, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine and tranylcypromine as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluoxetine; fluvoxamine; ketoconazole; omeprazole; sertraline; ticlopidine; tranylcypromine
1450933341	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:31649299	CYP2C19	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	< 0.001	530		European	Metabolism/PK	false	The harmonized sertraline serum concentrations in CYP2C19 PMs (carriers of 2 no function alleles) was 2.68-fold (p < 0.001, 95% confidence interval [CI] 2.16–3.31) higher compared to CYP2C19 NMs (*1/*1). A 3.00-fold (p < 0.001, 95% CI 2.46–3.66) higher concentration of N-desmethylsertraline was found in PMs compared to NMs. Compared with NMs, the N-desmethylsertraline-to-sertraline metabolic ratio was 1.26-fold higher in PMs (p = 0.009, 95% CI 1.07–1.46). In CYP2C19 PMs, the OR for having one or more TDM measurements above the target concentration range of 250 nM was 8.69 (p < 0.001, 95% CI 3.88–19.19). The study detected *2, *3, and *4 as no function alleles but did not report specific diplotypes. The diplotypes used in the annotations are representative.	sertraline
1451407140	rs6311	PMID:31792367	HTR2A	Allele T is associated with increased likelihood of Sexual Dysfunctions, Psychological due to citalopram or sertraline in people with Depressive Disorder, Major as compared to allele C.	yes	= 0.02	67		Unknown	Toxicity	false	Please note that alleles have been complemented to the positive strand.	citalopram; sertraline
981481642	rs13432159	PMCID:PMC3627503		Allele G is associated with increased general side-effects when treated with sertraline in people with Depressive Disorder, Major as compared to allele T.	yes	= 9.0E-8	113		Multiple groups, Individuals were included regardless of race or ethnicity	Toxicity	false	Side-effect presence and tolerance was measured by the Patient Rated Inventory of Side-Effects.	sertraline
1450931541	rs6313	PMID:30221791	HTR2A	Allele G is not associated with likelihood of Nausea and Vomiting due to citalopram and sertraline in people with Depressive Disorder, Major as compared to allele A.	no	= 0.13	65		Unknown	Toxicity	false	This variant is referred to in the paper as the 102 T/C SNP. Please note that alleles have been complemented to the positive strand.	citalopram; sertraline
1450415299	CYP2C19*1; CYP2C19*2	PMID:30983508	CYP2C19	CYP2C19 *1/*2 is not associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with citalopram, escitalopram or sertraline in people with Cardiovascular Diseases and Depression as compared to CYP2C19 *1/*1.	no	= 0.995	58	136	Unknown	Toxicity	false	For poor metabolizers exposed to sertraline, citalopram or escitalopram, providers changed prescribing patterns in response to alerts in the electronic medical record by either changing the drug, changing the dose or monitoring serial EKGs longitudinally. For intermediate metabolizers exposed to sertraline, citalopram or escitalopram, no alert was needed as no difference in QT was observed.	citalopram; escitalopram; sertraline
1184509867	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:19825907	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	no	= 0.10	59		East Asian	Efficacy	false	But the association was not significant. However, a significantly higher frequency of the s allele was observed in responders than in non-responders (chi square = 0.051, p=0.037).	sertraline
1183689534	rs1109866	PMID:24192121	ABCB6	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.386	276		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1184518441	CYP2C19*1; CYP2C19*11	PMID:21692664	CYP2C19	CYP2C19 *11 is associated with increased sensitivity to fluconazole, fluvoxamine and sertraline as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluconazole; fluvoxamine; sertraline
1183689529	rs4148739	PMID:24192121	ABCB1	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.	no	= 0.162	276		East Asian	Efficacy	false	Allele C was more frequent in the responders group. This association did not remain statistically significant after correction for false-discovery rate and genotypes were not significantly associated. Please note; alleles have been complemented to the plus chromosomal strand. This SNP was in strong LD with rs28401781.	citalopram; fluoxetine; paroxetine; sertraline
1449731933	rs1045642	PMID:29723928	ABCB1	Genotype AA is not associated with exposure to sertraline in healthy individuals as compared to genotypes AG + GG.	no	> 0.05	34		Unknown	Metabolism/PK	false	Please note that alleles have been complemented to the positive strand. A trend for individuals with the TT genotype to have reduced Cl/F of sertraline but this was not significant. These was no statistically significant association between rs1045642 and AUC, Cmax, half-life, Tmax or Vd/F of sertraline.	sertraline
827815008	rs6265	PMID:21338649	BDNF	Allele T is not associated with response to paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no		132		East Asian	Efficacy	false	Additionally, no correlation was observed between BDNF Val66Met polymorphism and serum BDNF levels at T0.	paroxetine; sertraline
1183920937	CYP2D6*3; CYP2D6*4	PMID:22775532	CYP2D6	CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is not associated with differences in treatment response when treated with citalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to CYP2D6 normal metabolizer.	no	> 0.05	39		Unknown	Efficacy	false	CYP2D6 metabolizer status had no significant effect on clinical response (p>0.05).32 patients were CYP2D6 EMs, 2 were UMs, 4 were IMs, and 1 patient was a PM. Exploratory association analysis of response to all 108 drug trials found a significant effect of CYP2D6 metabolizer status on response (Fisher's exact test: p=0.021) when comparing the patients with reduced CYP2D6 activity (IMs and PMs) to EMs or UMs, but no information regarding the direction of the association is given. AmpliChip CYP450 test, which detects up to 33 alleles, including 7 duplications in the CYP2D6 and 3 alleles in the CYP2C19 gene. PM, IM, EM, or UM status for CYP2D6 and PM or EM status for CYP2C19 using phenotyping software available with the AmpliChip CYP450 test.	citalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1449718352	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:16580768	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is not associated with response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	no	= 0.23	45		Multiple groups	Efficacy	false	No significant difference in HDRS score, CGI score or LUNSERS score between the different genotype groups.	sertraline
1184518432	CYP2C19*1; CYP2C19*10	PMID:21692664	CYP2C19	CYP2C19 *10 is not associated with sensitivity to celecoxib, fluconazole, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine, tranylcypromine and troglitazone as compared to CYP2C19 *1.	no					Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluconazole; fluvoxamine; ketoconazole; omeprazole; sertraline; ticlopidine; tranylcypromine; troglitazone
1450933318	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:31649299	CYP2C19	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) are associated with decreased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	< 0.001	816		European	Metabolism/PK	false	Compared with the CYP2C19 NMs (*1/*1), the sertraline serum concentration was increased 1.38-fold (p < 0.001, 95% CI 1.26–1.50) in CYP2C19 IMs (carriers of one no function alleles in combination with either *17 or *1). A 1.47-fold (p < 0.001, 95% CI 1.35–1.60)  higher concentration of N-desmethylsertraline was found in IMs. Compared with NMs, the N-desmethylsertraline-to-sertraline metabolic ratio was  1.14-fold higher ratio in IMs (p < 0.001, 95% CI 1.06–1.22). In CYP2C19 IMs, the OR for having one or more TDM measurements above the target concentration range of 250 nM was  1.97 (p = 0.064, CI: 1.21–3.21), compared to CYP2C19 NMs. Study identified *2, *3, and *4 as no function alleles but not reported specific diplotypes, the diplotypes in the annotations are used as a representation.	sertraline
1451407167	rs6313	PMID:31792367	HTR2A	Genotype AA is associated with increased likelihood of Sexual Dysfunctions, Psychological due to sertraline in people with Depressive Disorder, Major as compared to genotypes AG + GG.	no	= 0.06	67		Unknown	Toxicity	false	Please note that alleles have been complemented to the positive strand.	sertraline
1183699890	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:18677622	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 are associated with increased mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	< 0.05	66		Multiple groups, mainly White	Metabolism/PK	false	Genotyped for CYP2C9*2, *3 and *5; CYP2C19*2, *3, *4 ,*5 *17; and CYP2D6*3, *4, *6, *7, and *8. Additionally, CYP2D6 was analysed for gene deletion (*5) and gene multiplication. Regarding CYP2C19, patients are grouped into CYP2C19*1/*1, *1/def, *17/def, def/def,*1/*17, and *17/*17; only *2, *3, *17 were identified.	sertraline
1184169557	CYP2D6 normal metabolizers	PMID:23545896	CYP2D6	CYP2D6 normal metabolizers are associated with decreased number of failed medication trails when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder.	yes	= 0.007	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	Study observed that UM and PM both had undergone more medication trials than those with EM status (UM: median 3.5 trials (range 1-8), PM: median 5; EM: median 2 (range 1-9), IM: median 2 (range 1-7)). Significantly more non-EM than EM had undergone four or more drug trials (non-EM: 13/27 (48%) patients withgreater than or equal to4 trials; EM: 34/157 (22%) patients with greater than or equal to4 trials; P=0.007). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1184513240	rs57098334	PMID:17018806	SLC6A4	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.	yes	= 0.01	136		East Asian	Efficacy	false	Patients carrying the 12/12 VNTRs were compared to 9 and 10 VNTRs.	fluoxetine; sertraline
1183689550	rs6946119	PMID:24192121		Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.501	215		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1184169426	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:23545896	CYP2C19	CYP2C19 *1/*1 + *1/*17 + *2/*17 is not associated with treatment response when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	no	= 0.939	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	The association is for impact of CYP2D6 (P=0.743) or CYP2C19 (P=0.939) on overall response (defined see below). A nonsignificant trend for association of predicted CYP2C19 metabolizer status with treatment response to sertraline (P=0.064) was found but the direction of the association was not reported. Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1183689546	rs3755047	PMID:24192121	ABCB6	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.267	282		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1184518480	CYP2C19*1; CYP2C19*13	PMID:21692664	CYP2C19	CYP2C19 *13 is associated with decreased sensitivity to sertraline as compared to CYP2C19 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	sertraline
1183689542	rs3731885	PMID:24192121	ABCB6	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.345	281		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1183699907	CYP2C19*1; CYP2C19*17	PMID:18677622	CYP2C19	CYP2C19 *1/*17 + *17/*17 are not associated with differences in mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2C19 *1/*1.	no	> 0.05	66		Multiple groups, mainly White	Metabolism/PK	false	Genotyped for CYP2C9*2, *3 and *5; CYP2C19*2, *3, *4 ,*5 *17; and CYP2D6*3, *4, *6, *7, and *8. Additionally, CYP2D6 was analysed for gene deletion (*5) and gene multiplication. Regarding CYP2C19, patients are grouped into CYP2C19*1/*1, *1/def, *17/def, def/def,*1/*17, and *17/*17; only *2, *3, *17 were identified.	sertraline
1183689538	rs1109867	PMID:24192121	ABCB6	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.384	283		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
827921673	rs2032583	PMID:22641028	ABCB1	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.	yes	= 4.0E-4	424		Unknown	Toxicity	false	This SNP was significant alone and as part of a haplotype of 6 ABCB1 variants.	citalopram; fluvoxamine; paroxetine; sertraline; venlafaxine
1448102401	rs4291	PMID:27262302	ACE	Genotype TT is not associated with response to sertraline in people with Depressive Disorder.	no	= 0.803	55	71	Near Eastern	Efficacy	false	as compared to fluoxetine. Patients with major depressive disorder were randomized to receive sertraline or fluoxetine. Depression severity determined w/ the 21-item Hamilton Rating Scale for Depression (HAMD-21) before and after the treatment. Response calculated based on 50 % reduction in the reported scores. Given allele frequencies were compared between treatment groups in the responsive patients only.	sertraline
1183699929	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:18677622	CYP2D6	CYP2D6 *3 + *4 + *5 + *6 are not associated with differences in mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2D6 *1/*1.	no	> 0.3	66		Multiple groups, mainly White	Metabolism/PK	false	Genotyped for CYP2C9*2, *3 and *5; CYP2C19*2, *3, *4 ,*5 *17; and CYP2D6*3, *4, *6, *7, and *8. Additionally, CYP2D6 was analysed for gene deletion (*5) and gene multiplication. Regarding CYP2D6, study cohort diplotypes were not reported; CYP2D6 *3, *4, *5, and *6 were found. Gender and presence of variant alleles encoding impaired CYP2D6 and CYP2C9 enzyme activity were not significant as covariates (P>0.3) when  analysing the effect of CYP2C19 genotype on mean serum concentrations of sertraline and N-desmethyl sertraline.	sertraline
1184513231	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:17018806	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	yes	= 0.003	136		East Asian	Efficacy	false		fluoxetine; sertraline
1183689563	rs182694	PMID:24192121	ABCG1	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.642	278		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1447950096	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:26830411	CYP2C19	CYP2C19 *2 + *17 are not associated with metabolism of sertraline in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	no	= 1.0E-4	50		Unknown	Metabolism/PK	false	2C19*1/*2 n=12 2C19*2/*2 n=1 2C19*1/*17 n=11 2C19*2/*17 n=4 *1/*1 n=22	sertraline
1183689554	rs3747802	PMID:24192121	ABCB1	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.542	277		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1183699943	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:18677622	CYP2C9	CYP2C9 *2 + *3 are not associated with differences in mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2C9 *1/*1.	no	> 0.3	66		Multiple groups, mainly White	Metabolism/PK	false	Genotyped for CYP2C9*2, *3 and *5; CYP2C19*2, *3, *4 ,*5 *17; and CYP2D6*3, *4, *6, *7, and *8. Additionally, CYP2D6 was analysed for gene deletion (*5) and gene multiplication. Regarding CYP2C9, study cohort diplotypes were not reported; CYP2C9*2 and *3 were found. Gender and presence of variant alleles encoding impaired CYP2D6 and CYP2C9 enzyme activity were not significant as covariates (P>0.3) when  analysing the effect of CYP2C19 genotype on mean serum concentrations of sertraline and N-desmethyl sertraline.	sertraline
1183698918	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:11452243	CYP2C19	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with decreased clearance of sertraline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as normal metabolizer phenotype) .	yes	< 0.05	12		East Asian	Metabolism/PK	false	"The poor metabolizers had a 41% increase in sertraline AUC (P < .05) and a 51% increase in sertraline terminal elimination half-life ( P < .01) compared with extensive
metabolizers.  The AUC and Cmax of desmethylsertraline in poor metabolizers were significantly lower than  in extensive metabolizers (P < 0.05 and P < .01; respectively). Single dose of sertraline. Reported observation that two CYP2C19 poor metabolizers had some severe side effects of gastrointestinal disturbances at 2 hours after the administration of sertraline."	sertraline
1184483570	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:18452396	SLC6A4	SLC6A4 HTTLPR long form (L allele) is not associated with response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	no	> 0.05	64		Unknown	Efficacy	false	Response was measured using HAM-D and CGI- scores.	sertraline
1184483446	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:12955294	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.01	176		Unknown	Efficacy	false	The association was only significant for week 1 and 2 for response based on the CGI-I scale. A trend was found for weeks 4, 6, and 8, but it did not reach statistical significance. No significance was reached when using the HAM-D scale to assess response.	sertraline
1448531897	HLA-A*33:01:01	PMCID:PMC5367948	HLA-A	HLA-A *33:01:01 is associated with increased risk of drug-induced liver injury when treated with fenofibrate, sertraline, terbinafine or ticlopidine.	yes	= 7.0e-8	862	10588	European	Toxicity	false	The GWAS cohort includes DILI cases from a variety of drugs. The association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI.  rs114577328 was used as proxy marker for A*33:01 with high LD ( r2=0.98).	fenofibrate; sertraline; terbinafine; ticlopidine
1184518120	CYP2C19*1; CYP2C19*8	PMID:21692664	CYP2C19	CYP2C19 *8 is associated with decreased sensitivity to fluconazole, fluoxetine, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine, tranylcypromine and troglitazone as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluconazole; fluoxetine; fluvoxamine; ketoconazole; omeprazole; sertraline; ticlopidine; tranylcypromine; troglitazone
1448276512	rs2235015	PMID:26704739	ABCB1	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.	no	= 0.513	73		Unknown	Efficacy	false	Efficacy was measured as change in Hamilton Rating Scale for Depression (HAM-D-17). Patients were randomized to a high-dose arm and a normal-dose arm. Assessment made after 0, 7, 14, 21, and 28 days of treatment.	amitriptyline; citalopram; escitalopram; nortriptyline; paroxetine; Selective serotonin reuptake inhibitors; sertraline; trimipramine; venlafaxine
1450664580	rs3758581	PMID:21692664	CYP2C19	Allele G is not associated with sensitivity to celecoxib, fluconazole, fluoxetine, ketoconazole, omeprazole, sertraline, ticlopidine, tranylcypromine or troglitazone as compared to allele A.	no					Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluconazole; fluoxetine; ketoconazole; omeprazole; sertraline; ticlopidine; tranylcypromine; troglitazone
1450931459	rs17162912	PMID:29953682	DISP1	Allele C is not associated with response to citalopram, clomipramine, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to allele T.	no	> 0.05	112		European	Efficacy	false	No significant association between this variant and SRI or SSRI response using additive or dominant models. Note that this allele was not in HWE in the cohort (p=0.0008).	citalopram; clomipramine; fluoxetine; fluvoxamine; paroxetine; sertraline
1184518500	CYP2C19*1; CYP2C19*14	PMID:21692664	CYP2C19	CYP2C19 *14 is associated with decreased sensitivity to fluoxetine and sertraline as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluoxetine; sertraline
1184509540	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:21962566	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with posttraumatic stress disorder as compared to SLC6A4 HTTLPR short form (S allele).	yes	< 0.001	330		Unknown	Efficacy	false	Patients were assessed using the Clinician-Administered posttraumatic stress disorder Scale (CAPS). Response was defined as ¿30% improvement in CAPS total score with a CGI-I score of 1 or 2.	sertraline
1451407100	rs6265	PMID:31792367	BDNF; BDNF-AS	Allele T is not associated with likelihood of Sexual Dysfunctions, Psychological due to citalopram or sertraline in people with Depressive Disorder, Major as compared to allele C.	no		133		Unknown	Toxicity	false		citalopram; sertraline
1448102319	rs1799752	PMID:27262302	ACE	Genotype del/del is associated with increased response to sertraline in people with Depressive Disorder.	yes	= 0.0006	55	71	Near Eastern	Efficacy	false	as compared to fluoxetine. Patients with major depressive disorder were randomized to receive sertraline or fluoxetine. Depression severity determined w/ the 21-item Hamilton Rating Scale for Depression (HAMD-21) before and after the treatment. Response calculated based on 50 % reduction in the reported scores. Given allele frequencies were compared between treatment groups in the responsive patients only.	sertraline